HilleVax

HLVXPhase 3

HilleVax is a Boston-based biotech company dedicated to preventing life-threatening diseases through innovative vaccine development. Its primary asset, HIL-214, is a bivalent VLP vaccine targeting norovirus, a leading cause of severe acute gastroenteritis worldwide with no approved vaccines. The company was founded by experienced Takeda Vaccines executives and went public in 2022, positioning itself to advance its late-stage clinical program and build a pipeline of additional vaccine candidates.

Market Cap

$100M

Pipeline

2 in Phase 3

Patents

—

Publications

—

AI Company Overview

Infectious DiseaseVaccines

Technology Platform

Virus-like particle (VLP) vaccine platform for inducing strong immune responses against target pathogens.

Pipeline

4 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
HIL-214 + Placebo	Gastroenteritis	Phase 2/3
HIL-214 + Placebo	Gastroenteritis	Phase 2/3
HIL-214	Gastroenteritis	Phase 2
Placebo + HIL-214	Gastroenteritis	Phase 1

Opportunities

The primary opportunity is the massive, untapped global market for a norovirus vaccine, with no current approved products.

Success with HIL-214 could lead to inclusion in pediatric immunization schedules and create a platform for developing additional VLP-based vaccines against other infectious diseases.

Risk Factors

Key risks include clinical trial failure of the lead asset HIL-214, regulatory hurdles, future capital needs requiring dilutive financing, and the challenge of building a commercial organization or securing a favorable partnership for a first-to-market product.

Competitive Landscape

Main competitors include Vaxart (oral norovirus vaccine in Phase 2) and other early-stage programs. HilleVax differentiates through its advanced clinical stage (Phase 2b/3), experienced vaccine-focused leadership team, and its injectable bivalent VLP formulation aimed at providing broad protection.